SC Ianalumab considered safe, effective in Sjögren's syndrome
Findings from a recent trial showed ianalumab to be safe and well-tolerated in patients with moderate to severe primary Sjogren's syndrome. The study was published in the journal The Lancet on November 30, 2021.
Sjögren's syndrome is an immune system disorder characterized by dry eyes and mouth, systemic features, and reduced quality of life. Currently, there are no disease-modifying treatments. A new biologic, ianalumab (VAY736), with two modes of suppressing B cells, has previously shown preliminary efficacy.
For more details check out the full story in link below:
Subcutaneous Ianalumab Safe And Effective For Sjogren's Syndrome: Lancet
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd